Glimmerings of Hope From the Bottom of the Well

See allHide authors and affiliations

Science  30 Jul 1999:
Vol. 285, Issue 5428, pp. 656-657
DOI: 10.1126/science.285.5428.656

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Five years after the discovery that what were considered the two most promising AIDS vaccines could only stop laboratory-grown strains of HIV, the number of AIDS vaccines entering clinical trials is at an all-time low. But researchers are planning to begin testing a number of new approaches soon. Several combine versions of the vaccines that were derailed 5 years ago--which are based on HIV's surface protein, gp120--with others consisting of various HIV genes spliced into live, but harmless, "vectors," in hopes that the two will work in concert by stimulating different arms of the immune system. But some AIDS vaccine researchers have serious reservations about the results so far from tests of one such combination.